Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the MRC Translational Immune Discovery Unit have identified how rare populations of abnormal cells drive the formation and persistence of fistulas - painful, tunnel-like tracts that develop in around 30% of people with Crohn’s disease - paving the way for targeted treatments.

Spatial transcriptomics image showing a partially epithelialised fistula tract – this means parts of the tunnel have grown a new lining, while others have not. This is part of the disordered healing process that occurs in Crohn’s fistulas. Each colour in the image represents a different type of cell.

Crohn’s disease is a long-term disease that affects around 1 in every 650 people, in which parts of the gut become swollen, inflamed, and ulcerated. When ulcers or inflammation in the intestinal wall fail to heal properly, Crohn’s fistulas can form, burrowing into surrounding tissue and sometimes connecting to other organs or the skin. Precisely how these form, grow and persist has remained unclear, and they are very challenging to treat.

In this study, published in Nature, researchers analysed thousands of individual cells from Crohn’s fistulas, comparing them with healthy gut tissue. Using advanced single-cell and spatial analysis techniques, the team, led by the Simmons and Antanaviciute Groups, mapped the precise composition and behaviour of cells within the fistula tracts.

They discovered that fistulas are lined by concentric rings of “rogue” fibroblasts – cells that normally maintain tissue structure – that have become reprogrammed to act like cells involved in early fetal gut development. This out-of-context activity caused fibroblasts near the tract surface to destroy the surrounding tissue, promoting tunnelling, while deeper fibroblasts produced stiff, fibrotic material that stabilised and maintained the tunnels.

 

Read the full story on the MRC Weatherall Institute of Molecular Medicine (MRC WIMM) website.

Similar stories

New personalised therapy targets chronic blood cancer

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, according to a new study led by UCL and University of Oxford researchers.

Oxford researchers awarded ARIA funding to develop transformative anti-viral therapies

Three innovative research projects aimed at transforming how we protect against respiratory viruses, led by teams at the University of Oxford, have secured funding through the UK’s Advanced Research and Invention Agency (ARIA).

Study reveals blood stem cells can ‘remember’ inflammation

Researchers have discovered that some human blood stem cells retain a lasting “memory” of inflammation, a finding that could help explain links between ageing, chronic disease, and blood cancers

Reversing T cell exhaustion improves effectiveness of myeloma immunotherapies

Researchers at the Icahn School of Medicine at Mount Sinai, Bristol Myers Squibb (BMS), and the University of Oxford have discovered a way to give worn-out immune cells a second wind in the fight against multiple myeloma.

New study reveals how blood cell production responds to parasite infection

Research led by the Nerlov Group in the MRC Molecular Haematology Unit provides the first detailed explanation of how parasite-fighting immune cells are selectively increased following infection.

Oxford research highlights the global challenge of iron deficiency

Iron deficiency affects more than a billion people worldwide and remains a leading cause of anaemia. Oxford researchers are uncovering how iron levels shape immunity and infection - insights that could inform safer, more effective strategies to tackle iron deficiency globally.

Similar stories

New personalised therapy targets chronic blood cancer

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, according to a new study led by UCL and University of Oxford researchers.

Oxford researchers awarded ARIA funding to develop transformative anti-viral therapies

Three innovative research projects aimed at transforming how we protect against respiratory viruses, led by teams at the University of Oxford, have secured funding through the UK’s Advanced Research and Invention Agency (ARIA).

Study reveals blood stem cells can ‘remember’ inflammation

Researchers have discovered that some human blood stem cells retain a lasting “memory” of inflammation, a finding that could help explain links between ageing, chronic disease, and blood cancers

Reversing T cell exhaustion improves effectiveness of myeloma immunotherapies

Researchers at the Icahn School of Medicine at Mount Sinai, Bristol Myers Squibb (BMS), and the University of Oxford have discovered a way to give worn-out immune cells a second wind in the fight against multiple myeloma.

New study reveals how blood cell production responds to parasite infection

Research led by the Nerlov Group in the MRC Molecular Haematology Unit provides the first detailed explanation of how parasite-fighting immune cells are selectively increased following infection.

Oxford research highlights the global challenge of iron deficiency

Iron deficiency affects more than a billion people worldwide and remains a leading cause of anaemia. Oxford researchers are uncovering how iron levels shape immunity and infection - insights that could inform safer, more effective strategies to tackle iron deficiency globally.